Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Milne, Katy ^a   Alexander, Cheryl ^a   Webb, John R ^a,b   Sun, Winnie ^a   Dillon, Kristy ^a   Kalloger, Steve E ^c   Gilks, C Blake ^c   Clarke, Blaise ^d   Köbel, Martin ^e   Nelson, Brad H ^a,b,f  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Ovarian cancer; Prognosis; Tumor immunology; Tumor infiltrating lymphocytes

Indexed keywords

CARBOPLATIN; CD20 ANTIGEN; PACLITAXEL;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOLOGY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVARY CANCER; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR VOLUME; COHORT ANALYSIS; COST OF ILLNESS; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; NEOPLASM; NEUTROPHIL; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

COHORT STUDIES; COST OF ILLNESS; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; NEUTROPHILS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84857376683     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-33     Document Type: Article

References (45)

1. Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010, 29:203-211. 10.1097/PGP.0b013e3181c042b6, 20407318.
2. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, Sessa C, Castiglione M. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v23-v30.
3. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213. 10.1056/NEJMoa020177, 12529460.
4. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008, 222:101-116. 10.1111/j.1600-065X.2008.00614.x, 18363996.
5. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102:18538-18543. 10.1073/pnas.0509182102, 1311741, 16344461.
6. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007, 104:3360-3365. 10.1073/pnas.0611533104, 1805580, 17360651.
7. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009, 22:393-402. 10.1038/modpathol.2008.191, 19060844.
8. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 2009, 58:449-459. 10.1007/s00262-008-0583-5, 18791714.
9. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009, 4:e6412. 10.1371/journal.pone.0006412, 2712762, 19641607.
10. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010, 185:4977-4982. 10.4049/jimmunol.1001323, 20962266.
11. Bain B, Seed M, Godsland I. Normal values for peripheral blood white cell counts in women of four different ethnic origins. J Clin Pathol 1984, 37:188-193. 10.1136/jcp.37.2.188, 498676, 6693578.
12. Evans DM, Frazer IH, Martin NG. Genetic and environmental causes of variation in basal levels of blood cells. Twin Res 1999, 2:250-257. 10.1375/136905299320565735, 10723803.
13. Datta S, Sarvetnick N. Lymphocyte proliferation in immune-mediated diseases. Trends Immunol 2009, 30:430-438. 10.1016/j.it.2009.06.002, 19699149.
14. Bender BS, Nagel JE, Adler WH, Andres R. Absolute peripheral blood lymphocyte count and subsequent mortality of elderly men. The Baltimore Longitudinal Study of Aging. J Am Geriatr Soc 1986, 34:649-654.
15. Porrata LF, Markovic SN. Is absolute lymphocyte count just another prognostic factor in cancer?. SRX Medicine 2010 2010, , http://www.hindawi.com/archive/2010/812304/
16. Riesco A. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 1970, 25:135-140. 10.1002/1097-0142(197001)25:1<135::AID-CNCR2820250120>3.0.CO;2-9, 5410303.
17. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009, 69:5383-5391. 10.1158/0008-5472.CAN-08-3845, 2775079, 19549917.
18. Wolff JP, de Oliveira CF. Lymphocytes in patients with ovarian cancer. Obstet Gynecol 1975, 45:656-658. 10.1097/00006250-197506000-00011, 1143727.
19. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009, 58:15-23. 10.1007/s00262-008-0516-3, 18414853.
20. Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, Giani L, Vaghi M, Ardizzoia A, Gardani GS. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004, 19:135-140.
21. Nieto Y, Shpall EJ, McNiece IK, Nawaz S, Beaudet J, Rosinski S, Pellom J, Slat-Vasquez V, McSweeney PA, Bearman SI, et al. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clin Cancer Res 2004, 10:5076-5086. 10.1158/1078-0432.CCR-04-0117, 15297410.
22. Ferrandina G, Pierelli L, Perillo A, Rutella S, Ludovisi M, Leone G, Mancuso S, Scambia G. Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications. Clin Cancer Res 2003, 9:195-200.
23. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, et al. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One 2008, 3:e3409. 10.1371/journal.pone.0003409, 2561074, 18923710.
24. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009, 6:e1000114. 10.1371/journal.pmed.1000114, 2711307, 19636370.
25. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010, 102:26-38. 10.1093/jnci/djp438, 2802285, 20042715.
26. Bishara S, Griffin M, Cargill A, Bali A, Gore ME, Kaye SB, Shepherd JH, Van Trappen PO. Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2007, E-pub.
27. Sharma R, Hook J, Kumar M, Gabra H. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 2008, 44:251-256. 10.1016/j.ejca.2007.11.011, 18155897.
28. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000, 10:33-41.
29. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994, 73:1882-1888. 10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R, 8137215.
30. Maeda K, Malykhin A, Teague-Weber BN, Sun XH, Farris AD, Coggeshall KM. Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals. Blood 2009, 113:4534-4540. 10.1182/blood-2008-12-192559, 2680362, 19224760.
31. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol 2001, 12:1423-1432. 10.1023/A:1012527006566, 11762815.
32. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, Sugisaki Y. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000, 83:196-203. 2363477, 10901370.
33. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, Carbone DP. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007, 110:624-631. 10.1182/blood-2007-01-065714, 1924481, 17376891.
34. Turrel F, Guignant C, Venet F, Lepape A, Monneret G. Innovative therapeutic strategies for restoring lymphocyte functions in septic patients. Inflamm Allergy Drug Targets 2008, 7:181-186. 10.2174/187152808785748173, 18782025.
35. Takeyama Y, Takas K, Ueda T, Hori Y, Goshima M, Kuroda Y. Peripheral lymphocyte reduction in severe acute pancreatitis is caused by apoptotic cell death. J Gastrointest Surg 2000, 4:379-387. 10.1016/S1091-255X(00)80016-5, 11058856.
36. Okada H, Kobune F, Sato TA, Kohama T, Takeuchi Y, Abe T, Takayama N, Tsuchiya T, Tashiro M. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. Arch Virol 2000, 145:905-920. 10.1007/s007050050683, 10881678.
37. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol 2009, 183:3720-3730. 10.4049/jimmunol.0900970, 19692638.
38. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol 2005, 62:161-172.
39. Overwijk WW, Schluns KS. Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol 2009, 132:153-165. 10.1016/j.clim.2009.03.512, 2761713, 19428306.
40. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001, (19):3477-3482.
41. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 2003, 26:394-402. 10.1097/00002371-200309000-00002, 12973028.
42. Uggeri F, Caprotti R, De Grate L, Crippa S, Nobili C, Penati C, Romano F. Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: a randomized study. Hepatogastroenterology 2009, 56:861-865.
43. Lissoni P, Brivio F, Fumagalli L, Di Fede G, Brera G. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy. In Vivo 2005, 19:1077-1080.
44. Romano F, Cesana G, Berselli M, Gaia Piacentini M, Caprotti R, Bovo G, Uggeri F. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol 2004, 88:240-247. 10.1002/jso.20155, 15565596.
45. Sportes C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010, 16:727-735. 10.1158/1078-0432.CCR-09-1303, 2808195, 20068111.